Predictive and Prognostic Value of CA 19-9 in Resected Pancreatic Adenocarcinoma

被引：0
|
作者：
Joshua G. Barton
John P. Bois
Michael G. Sarr
Christina M. Wood
Rui Qin
Kristine M. Thomsen
Michael L. Kendrick
Michael B. Farnell
机构：
[1] Mayo Clinic,Department of Surgery, Division of GI and General Surgery
[2] Mayo Clinic,Division of Biostatistics
来源：
Journal of Gastrointestinal Surgery | 2009年 / 13卷
关键词：
Pancreatic carcinoma; Pancreatic ductal carcinoma; CA 19-9 antigen; Survival analysis; Predictive value of tests;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2050 / 2058
页数：8
相关论文
共 50 条
  • [21] Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine
    Ziske, C
    Schlie, C
    Gorschlüter, M
    Glasmacher, A
    Mey, U
    Strehl, J
    Sauerbruch, T
    Schmidt-Wolf, IGH
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 (08) : 1413 - 1417
  • [22] Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine
    C Ziske
    C Schlie
    M Gorschlüter
    A Glasmacher
    U Mey
    J Strehl
    T Sauerbruch
    I G H Schmidt-Wolf
    [J]. British Journal of Cancer, 2003, 89 : 1413 - 1417
  • [23] 53BP1 expression is a modifier of the prognostic value of lymph node ratio and CA 19-9 in pancreatic adenocarcinoma
    Ausborn, Natalie L.
    Wang, Tong
    Wentz, Sabrina C.
    Washington, Mary Kay
    Merchant, Nipun B.
    Zhao, Zhiguo
    Shyr, Yu
    Chakravarthy, Anuradha Bapsi
    Xia, Fen
    [J]. BMC CANCER, 2013, 13
  • [24] 53BP1 Expression Is a Modifier of the Prognostic Value of Lymph Node Ratio and CA 19-9 in Pancreatic Adenocarcinoma
    Ausborn, N.
    Wang, T.
    Wentz, S. C.
    Washington, M. K.
    Merchant, N. B.
    Zhao, Z.
    Shyr, Y.
    Chakravarthy, A. B.
    Xia, F.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S309 - S309
  • [25] Postresection CA 19-9 Value as a Prognostic Factor Response
    Seo, Yuji
    Kinsella, Timothy J.
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (03): : 320 - 320
  • [26] Postresection CA 19-9 Value as a Prognostic Factor Response
    Seo, Yuji
    Kinsella, Timothy J.
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (01): : 107 - 107
  • [27] CA 19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma
    Ali C.W.
    Kaye T.F.
    Adamson D.J.A.
    Tait I.S.
    Polignano F.M.
    Highley M.S.
    [J]. Journal of Gastrointestinal Cancer, 2007, 38 (2-4) : 108 - 114
  • [28] Prognostic value of CA19-9 in patients with pancreatic adenocarcinoma after chemoradiotherapy
    Nampei, Y.
    Toyomasu, Y.
    Ochiai, S.
    Mase, T.
    Watanabe, Y.
    Kawamura, T.
    Takada, A.
    Yamashita, Y.
    Li, N.
    Sakuma, H.
    Nomoto, Y.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S568 - S569
  • [29] Predictive value of serum carbohydrate antigen 19-9 (CA19-9) for early mortality in advanced pancreatic cancer
    Junior P.L.S.U.
    Callegaro-Filho D.
    Bugano D.D.G.
    Moura F.
    Maluf F.C.
    [J]. Journal of Gastrointestinal Cancer, 2018, 49 (4) : 481 - 486
  • [30] Elevated CA 19-9 is associated with worse survival in patients with resected ampullary adenocarcinoma
    Boyev, Artem
    Prakash, Laura R.
    Chiang, Yi-Ju
    Newhook, Timothy E.
    Bruno, Morgan L.
    Arvide, Elsa M.
    Dewhurst, Whitney L.
    Kim, Michael P.
    Ikoma, Naruhiko
    Lee, Jeffrey E.
    Snyder, Rebecca A.
    Tzeng, Ching-Wei D.
    Katz, Matthew H. G.
    Maxwell, Jessica E.
    [J]. SURGICAL ONCOLOGY-OXFORD, 2023, 51
12345